QT Vascular assures investors over suit
CEO: Minimal probability of a permanent injunction against its Chocolate PTA balloon catheter
Singapore
QT VASCULAR has assured investors in an update on the ongoing litigation involving specialty balloon angioplasty company AngioScore Inc during its annual general meeting on Thursday last week.
In June 2012, AngioScore initiated patent infringement proceedings against QT subsidiaries TriReme Medical and Quattro Vascular, as well as QT Vascular's chief executive Eitan Konstantino in relation to the Chocolate PTA balloon catheter. AngioScore's claim is that QT Vascular's Chocolate PTA infringes the '119 Patent - a patent that claims a very specific design for an angioplasty balloon catheter and a non-deployable stent.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
Chevron's quarterly profit beats estimates
EU toughens rules on Chinese fashion retailer Shein
Keppel prices 70 million euros of floating-rate notes due 2031
Mixed trading in Asia as investors watch for further macro data; STI down 0.2%
Shareholders raise questions over dividend payout, directors’ salaries at Best World AGM ahead of proposed privatisation